The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [.sup.68Ga]GaCl.sub.3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.

Structure and luminescence properties of a new Cu-Cyteamine (Cu-Cy) crystal material are provided. The crystal structure of the Cu-Cy is determined by single crystal X-ray diffraction. It is found that the compound crystallizes in the monoclinic space group C2/c and cell parameters are a=7.5510(4) , b=16.9848(7) , c=7.8364(4) , =104.798(3). The new Cu-Cy crystal material of the invention is also useful for treatment of cancer.

The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.

The invention relates to octadentate ligands of a general formula R.sup.1-D-X-D-X-D-X-D-E-R.sup.2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R.sup.1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R.sup.2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.

A multimodal contrast and radiopharmaceutical agent for an imaging and a targeted therapy guided by imaging.

Structure and luminescence properties of a new Cu-Cyteamine (Cu-Cy) crystal material are provided. The crystal structure of the Cu-Cy is determined by single crystal X-ray diffraction. It is found that the compound crystallizes in the monoclinic space group C2/c and cell parameters are a=7.5510(4) , b=16.9848(7) , c=7.8364(4) , =104.798(3). The new Cu-Cy crystal material of the invention is also useful for treatment of cancer.

A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide generator to a composition comprising a pharmaceutically acceptable buffer and optionally also a pharmaceutically acceptable basic reagent, in amounts sufficient to increase the pH to a level in the range of 3 to 8, wherein the composition further comprises a chelator that is able to chelate radioactive gallium within said pH range and at moderate temperature, said chelator being optionally linked to a biological targeting agent. Kits and compositions for use in the method are also described and claimed.

Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

Antimony (Sb) chelates for use in targeted auger therapy and imaging diagnostics are provided. Also provided are methods of treating a subject in need of treatment using the antimony chelates. The chelates comprise a chelating ligand that binds an Sb radionuclide in a +5-oxidation state, such as .sup.119Sb and .sup.117Sb. The chelating ligand renders the Sb radionuclide stable and inert in vivo and enables the conjugation of the chelate to a biological targeting vector.

The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.